SMARCB1 and rhabdoid tumor: Conversely, BAF47 appeared not needed for the proliferative arrest, as reported in rhabdoid tumors with loss of SMARCB1 (as reviewed by Kohashi and Oda, 2017), observed after SS18-SSX depletion (McBride et al., 2018).